Article

Sponsored Content

Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID

Author(s):

Frontage Laboratories, Inc.

In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Content
Site Logo
August 2nd 2025

Leveraging remote-based regional hubs in FSP partnerships

PPD™ FSP solutions
Site Logo
August 2nd 2025

Establishing a Bespoke Outsourcing Arrangement with Hybrid FSP/FSO Partnerships

PPD™ FSP solutions
Site Logo
August 2nd 2025

2025 FSP Trends Report

PPD™ FSP solutions
Site Logo
August 2nd 2025

Focus on biotech: Harnessing FSP engagements to deliver on-time, on-budget

PPD™ FSP solutions
Site Logo
August 2nd 2025

FSP Outsourcing in Clinical Research: Trends and Opportunities

PPD
When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
Site Logo
August 2nd 2025

Unlock Commercial Growth through Data-Driven Patient and HCP Insights

Inovalon
Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
© 2025 MJH Life Sciences

All rights reserved.